Conclusion: Bone markers in metastatic bone disease

被引：10

作者：

Coleman, RE ^{[1
]}

机构：

[1] Weston Pk Hosp, Canc Res Ctr, Acad Unit Clin Oncol, Sheffield S10 2SJ, S Yorkshire, England

来源：

CANCER TREATMENT REVIEWS | 2006年 / 32卷

关键词：

metastatic bone disease; bone markers; NTX; skeletal-related event; BAP;

D O I：

10.1016/S0305-7372(06)80007-1

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Bone metastases occur frequently in patients with multiple myeloma and breast, prostate, and lung cancer. Presence of metastatic bone disease (MBD) is correlated with abnormal bone remodelling, as high levels of biochemical markers of bone turnover tan be detected in serum or urine from patients with these malignancies. The idea of using bone markers in the diagnosis and follow-up of patients with MBD is undergoing validation and gaining acceptance. In this conclusion, we summarise data from leading studies relating to the search for useful markers of bone resorption and bone formation in MBD. (c) 2006 Elsevier.Ltd. All rights reserved.

引用

页码：27 / 28

页数：2